Mantu Gupta, MD
Urology · New York, NYNPI 1114981370
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $153,528 of the $229,491 with a category attached, or 66.9%. Boston Scientific accounts for 69.7% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $62,517 and has fallen 75.6% since, to $15,256 in 2025. Among urology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $605.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$160K
- Olympus America Inc.$42K
- Lumenis, Inc$7K
- Travere Therapeutics, Inc.$7K
- Alnylam Pharmaceuticals Inc.$6K
- Lumenis Ltd.$2K
- plus $5K from 29 others
Across 10 payments — averaging $18,935 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gyrus ACMI, Inc.$166K
- Boston Scientific$23K
What the payments were for
- Consulting fees$58,05525%
- Speaking & faculty fees$153,52867%
- Travel & lodging$4,3952%
- Food & beverage$13,3676%
- Education$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 228 | $159,986 |
| Olympus America Inc. | 39 | $42,296 |
| Lumenis, Inc | 2 | $7,158 |
| Travere Therapeutics, Inc. | 20 | $6,987 |
| Alnylam Pharmaceuticals Inc. | 15 | $6,098 |
| Lumenis Ltd. | 2 | $2,000 |
| Olympus Winter & Ibe GmbH | 1 | $1,080 |
| Olympus Corporation Of The Americas | 2 | $871 |
| Olympus Corporation | 1 | $540 |
| Coloplast | 12 | $312 |
| Procept Biorobotics Corporation | 4 | $303 |
| Calyxo, Inc. | 2 | $255 |
| Urogen Pharma, Inc. | 9 | $232 |
| Myovant Sciences Inc. | 10 | $146 |
| Gyrus ACMI, Inc. | 1 | $134 |
| Micro-tech Endoscopy USA, Inc. | 1 | $133 |
| Ambu Inc. | 1 | $121 |
| Ferring Pharmaceuticals Inc. | 1 | $117 |
| Novo Nordisk Health Care AG | 1 | $114 |
| Merck | 4 | $81 |
| Pfizer | 4 | $73 |
| Novo Nordisk | 2 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $56 |
| AbbVie | 2 | $50 |
| Rochester Medical Corporation | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 1 | $34 |
| Novartis | 1 | $30 |
| Hollister Incorporated | 1 | $27 |
| Progenics Pharmaceuticals, Inc. | 1 | $27 |
| Blue Earth Diagnostics | 1 | $27 |
| Gilead | 1 | $27 |
| Astellas Pharma US Inc | 1 | $24 |
| Abiomed | 1 | $19 |
| 180 Medical, Inc. | 1 | $17 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$67,851
- Dornier MedTech$14,006
- Soltive$13,228
- ShockPulse - SE$9,030
- UGN Laser Capital$8,100
- UGN Laser Fibers$8,100
- (815) Thiola$6,701
- OXLUMO$5,670
- Lumenis Pulse 120H$5,260
- Tria Firm$4,168
- LithoVue$3,045
- GENERAL - THERAPIES$2,561
- GENERAL ONCOLOGY$1,500
- Single Use Repositionable Clip$1,080
- LITHOCLAST$519
- Moses 550 D\F\L$500
- NAVIGUIDE$350
- AquaBeam Robotic System$219
- CVAC Aspiration System$217
- PERCUTANEOUS TRACT KIT$153
How this compares
$229,491 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 543 | $66,120 |
| MyrbetriqMirabegron | 74 | $47,017 |
| Tamsulosin Hcl | 282 | $4,249 |
| Chlorthalidone | 182 | $3,415 |
| Klor-Con-EfPotassium Bicarbonate/Cit Ac | 20 | $3,142 |
| Methenamine Hippurate | 22 | $2,913 |
| Finasteride | 162 | $2,177 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 53 | $1,076 |
| Oxybutynin Chloride ErOxybutynin Chloride | 30 | $958 |
| Dutasteride | 38 | $911 |
| Cefpodoxime Proxetil | 20 | $816 |
| Allopurinol | 61 | $569 |
| Effer-KPotassium Bicarbonate/Cit Ac | 20 | $566 |
| NitrofurantoinNitrofurantoin Macrocrystal | 20 | $563 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $24 | $47,01774 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 urology providers in New York.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Robin SmithNew York$215K
- Jean-Francois EidNew York$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.